<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910819-0134</DOCNO><DOCID>910819-0134.</DOCID><HL>   Genetics Institute Inc.   Assets Are Attached   Pending Amgen Suit</HL><DATE>08/19/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A5C</SO><CO>   AMGN GENI</CO><MS>TECHNOLOGY (TEC)</MS><IN>MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><GV>JUSTICE DEPARTMENT (JUS)</GV><RE>CALIFORNIA (CA)MASSACHUSETTS (MA)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   CAMBRIDGE, Mass. -- Genetics Institute Inc. said a federalcourt in Boston granted Amgen Inc. a $25 million &quot;attachment&quot;against certain of Genetics Institute's assets to coverpotential damages awarded as a result of a patentinfringement lawsuit.   Damages stemming from the lawsuit, which was filed overrights to the anti-anemia drug erythropoietin, or EPO,haven't yet been decided. The court's decision means thatGenetics Institute can't &quot;sell or encumber with debt&quot; theattached real estate assets, said a spokeswoman for GeneticsInstitute.</LP><TEXT>   Genetics Institute in March took a special charge and setaside $11 million for possible damages after it lost adrawn-out patent battle over EPO to Amgen, based in ThousandOaks, Calif. Genetics Institute Friday reiterated itsprevious assertion that the charge &quot;should be sufficient tocover the damages it may be required to pay to Amgen.&quot;   In announcing the federal court's attachment of itsproperty, Genetics Institute disclosed that BoehringerMannheim G.m.b.H., which has licensed European rights toGenetics Institute's version of EPO, has agreed to indemnifyGenetics Institute for an additional $11 million of possibledamages stemming from the case. Genetics Institute added that&quot;this indemnity should limit its ultimate exposure to the $11million charge already taken.&quot;   An Amgen spokesman said the biotechnology company hasn'tyet calculated its damages in the case. &quot;Those will bedetermined during the {legal} discovery process,&quot; which willbegin soon. &quot;When that's finished, we'll file a motion andthe judge will make a decision.&quot;   Proceedings to determine damages in the case are expectedto begin in April or May next year, Genetics Institute said.Meanwhile, the company has asked the U.S. Supreme Court toconsider overturning the federal appeals court decision inMarch in favor of Amgen.</TEXT></DOC>